Trial Profile
A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux ) in EGFR Expressing Metastatic Colorectal Cancer (CRC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Therapeutic Use
- 25 Aug 2015 Protocol has been amended to change in treatment arms, as per ClinicalTrials.gov record.
- 25 Aug 2015 Protocol has been amended to change in treatment arms, as per ClinicalTrials.gov record.
- 10 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.